Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) agreed to renew its trademark license agreement with the Shandong Xinhua Pharmaceutical Branch of Hualu Holdings for the full year 2025, a Tuesday Hong Kong bourse filing said.
The company has been using the trademark Xinhua and as it still plans to do so in the future, it agreed to renew the license agreement with the other party.
Under the renewed agreement, the company will pay 10 million yuan in annual license fee to the other party for the exclusive right to use the Trademark.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.